# Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults

> **NCT01228383** · PHASE2 · COMPLETED · sponsor: **Crucell Holland BV** · enrollment: 240 (actual)

## Conditions studied

- Rabies

## Interventions

- **BIOLOGICAL:** Rabies virus-specific monoclonal antibodies
- **BIOLOGICAL:** human polyclonal rabies immune globulin (HRIG)
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Human diploid cell vaccine (HDCV)
- **BIOLOGICAL:** Purified verocell rabies vaccine (PVRV)

## Key facts

- **NCT ID:** NCT01228383
- **Lead sponsor:** Crucell Holland BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2012-10
- **Final completion:** 2012-12
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2013-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01228383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01228383, "Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01228383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*